Serum IgG N‐glycans enable early detection and early relapse prediction of colorectal cancer
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Colorectal cancer (CRC) develops mainly from colorectal advanced adenomas (AA), which are considered precancerous lesions. Novel early diagnostic biomarkers are urgently needed to distinguish CRC and AA from healthy control (HC). Alternative glycosylation of serum IgG has been shown to be closely associated with CRC. We aimed to explore the potential of IgG N-glycan as biomarkers in the early differential diagnosis of CRC. The study population was strictly matched to the exclusion criteria process. Serum IgG N-glycan profiles were analyzed by a robust and reliable relative quantitative method based on ultra-performance liquid chromatography (UPLC). Relative quantification and classification performance of IgG N-glycans were evaluated by Mann-Whitney U tests and ROC curve based on directly detected and derived glycan traits, respectively. Six and 14 directly detected glycan traits were significantly changed in AA and CRC, respectively, compared with HC. GP1 and GP3 were able to accurately distinguish AA from HC for early precancerous lesions screening. GP4 and GP14 provided a high value in discriminating CRC from HC. A novel combined index named GlycoF, including GP1, GP3, GP4, GP14 and CEA was developed to provide a potential early diagnostic biomarker in discriminating simultaneously AA (AUC = 0.847) and CRC (AUC = 0.844) from HC. GlycoF also demonstrated a superior CRC detection rate across CRC all stages and conspicuous prediction ability of risk of relapse. Serum IgG N-glycans analysis provided powerful early screening biomarkers that can efficiently differentiate CRC and AA from HC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Serum <scp>IgG</scp> N‐glycans enable early detection and early relapse prediction of colorectal cancer
- Date Crossref
- 03/10/2022
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fudan University NHC Key Laboratory of Glycoconjugates Research pays non établi dans la noticeUniversité ou école supérieure
-
Shanghai East Hospital pays non établi dans la noticeÉtablissement de santé
-
Shanghai Jiao Tong University Department of General Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Shanghai First People's Hospital pays non établi dans la noticeÉtablissement de santé
-
School of Basic Medical Sciences NHC Key Laboratory of Glycoconjugates Research pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine Tongji University Shanghai China Department of Gastroenterology pays non établi dans la noticeUniversité ou école supérieure
NHC Key Laboratory of Glycoconjugates Research — Fudan University, Shanghai East Hospital et Department of General Surgery — Shanghai Jiao Tong University, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.